News Column

New Stroke Findings from Z.J. Tan and Co-Researchers Described (Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate...

September 10, 2014



New Stroke Findings from Z.J. Tan and Co-Researchers Described (Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6 h after ischemic stroke in aged female rats)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Stroke have been published. According to news reporting originating from St. Louis, Missouri, by NewsRx correspondents, research stated, "Recombinant tissue plasminogen activator (r-tPA) is the only FDA-approved drug treatment for ischemic stroke and must be used within 4.5 h. Thrombolytic treatment with r-tPA has deleterious effects on the neurovascular unit that substantially increases the risk of intracerebral hemorrhage if administered too late. These therapeutic shortcomings necessitate additional investigation into agents that can extend the therapeutic window for safe use of thrombolytics."

Our news editors obtained a quote from the research, "In this study, combination of r-tPA and APT102, a novel form of human apyrase/ADPase, was investigated in a clinically-relevant aged-female rat embolic ischemic stroke model. We propose that successfully extending the therapeutic window of r-tPA administration would represent a significant advance in the treatment of ischemic stroke clue to a significant increase in the number of patients eligible for treatment. Results of our study showed significantly reduced mortality from 47% with r-tPA alone to 16% with co-administration of APT102 and r-tPA. Co-administration decreased cortical (47 5% vs. 29 5%), striatal (50 +/- 2%, vs. 40 +/- 3%) and total (48 +/- 3%vs. 33 +/- 4%) hemispheric infarct volume compared to r-tPA alone. APT102 improved neurological outcome (8.9 +/- 0.6, vs. 6.8 0.8) and decreased hemoglobin extravasation in cortical tissue (1.9 +/- 0.1 mg/dl vs. 14 +/- 0.1 mg/dl) striatal tissue (2.1 +/- 0.3 mg/dl vs. 1.4 +/- 0.1 mg/dl) and whole brain tissue (2.0 +/- 0.2 mg/dl vs. 1.4 +/- 0.1 mg/dl). These data suggest that APT102 can safely extend the therapeutic window for r-tPA mediated reperfusion to 6 h following experimental stroke without increased hemorrhagic transformation."

According to the news editors, the research concluded: "APT102 offers to be a viable adjunct therapeutic option to increase the number of clinical patients eligible for thrombolytic treatment after ischemic stroke."

For more information on this research see: Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6 h after ischemic stroke in aged female rats. European Journal of Pharmacology, 2014;738():368-373. European Journal of Pharmacology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmacology - www.elsevier.com/wps/product/cws_home/506087)

The news editors report that additional information may be obtained by contacting Z.J. Tan, APT Therapeut Inc, St Louis, MO 63108, United States. Additional authors for this research include X.L. Li, R.C. Turner, A.F. Logsdon, B. Lucke-Wold, K. DiPasquale, S.S. Jeong, R.D. Chen, J.D. Huber and C.L. Rosen (see also Stroke).

Keywords for this news article include: St. Louis, Missouri, United States, North and Central America, Angiology, Stroke, Therapeutics, Therapy, Thrombolytic

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters